Tejara Capital Ltd purchased a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 130,979 shares of the company's stock, valued at approximately $11,239,000. Establishment Labs makes up approximately 4.6% of Tejara Capital Ltd's investment portfolio, making the stock its 3rd biggest holding. Tejara Capital Ltd owned approximately 0.45% of Establishment Labs at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Establishment Labs in the 2nd quarter valued at approximately $135,752,000. Rice Hall James & Associates LLC acquired a new position in Establishment Labs during the second quarter worth $48,134,000. Goldman Sachs Group Inc. increased its holdings in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company's stock worth $59,145,000 after buying an additional 438,206 shares during the last quarter. Viking Global Investors LP acquired a new position in Establishment Labs during the second quarter worth $14,669,000. Finally, Soleus Capital Management L.P. bought a new stake in Establishment Labs during the second quarter worth $9,050,000. Institutional investors and hedge funds own 72.91% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have commented on ESTA. JPMorgan Chase & Co. increased their price target on shares of Establishment Labs from $84.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a research note on Thursday, August 6th. Mizuho upped their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday, July 15th. TD Cowen raised their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Finally, BTIG Research lifted their price target on Establishment Labs from $96.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $100.25.
View Our Latest Analysis on Establishment Labs
Establishment Labs Stock Down 5.1%
ESTA opened at $71.52 on Friday. The stock's fifty day simple moving average is $86.38 and its 200 day simple moving average is $74.85. Establishment Labs Holdings Inc. has a 1-year low of $36.53 and a 1-year high of $97.59. The stock has a market cap of $2.13 billion, a PE ratio of -54.60 and a beta of 1.07. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.05). The company had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company's revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.57) earnings per share. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.
Establishment Labs Profile
(
Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Featured Articles
Want to see what other hedge funds are holding ESTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
